SCHEMBL6521035

SCHEMBL6521035

CCOc1ncccc1C1(OC(=O)N2CCC(C3CCN(CC)CC3)CC2)C(=O)N(S(=O)(=O)c2ccccc2)c2ccc(C#N)cc21

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
AVPR1B P47901 12/20 0.44
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
KMT2A Q03164 1/20 0.40
GAA P10253 1/20 0.37
CYP3A4 P08684 1/20 0.37
FNTA P49354 2/20 0.36
FNTB P49356 2/20 0.36
KCNH2 Q12809 1/20 0.35
GPR6 P46095 1/20 0.35
PGGT1B P53609 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6526260 0.97 AVPR1B (0.47) AVPR1BHCRTR1HCRTR2KMT2AGAA
SCHEMBL6523825 0.95 AVPR1B (0.43) AVPR1BHCRTR1HCRTR2KMT2AGAA
SCHEMBL6520270 0.94 AVPR1B (0.45) AVPR1BHCRTR1HCRTR2KMT2AGAA
SCHEMBL6520248 0.94 AVPR1B (0.49) AVPR1BHCRTR1HCRTR2CYP3A4GPR6
SCHEMBL6523933 0.93 AVPR1B (0.44) AVPR1BHCRTR1HCRTR2KMT2AGAA
SCHEMBL3265705 0.93 AVPR1B (0.43) AVPR1BHCRTR1HCRTR2KMT2AGAA
SCHEMBL6523184 0.93 AVPR1B (0.43) AVPR1BHCRTR1HCRTR2KMT2ACYP3A4
SCHEMBL6517569 0.92 AVPR1B (0.48) AVPR1BHCRTR1HCRTR2GAACYP3A4
SCHEMBL6517584 0.92 AVPR1B (0.43) AVPR1BHCRTR1HCRTR2KMT2AGAA
SCHEMBL6520197 0.91 AVPR1B (0.52) AVPR1BHCRTR1HCRTR2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703774-B2 Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases AbbVie Deutschland GmbH & Co. KG (DE) 2014-04-22 US claimed
US-20160362394-A1 CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES ABBVIE DEUTSCHLAND (DE) 2016-12-15 US disclosed
US-9422264-B2 Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases AbbVie Deutschland GmbH & Co. KG (DE) 2016-08-23 US disclosed
US-20140315914-A1 CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES AbbVie Deutschland GmbH & Co. KG (DE) 2014-10-23 US disclosed
US-8703774-B2 Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases AbbVie Deutschland GmbH & Co. KG (DE) 2014-04-22 US disclosed
US-20110065720-A1 CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES ABOTT GMBH & CO KG (DE) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160362394-A1 CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES AVPR2, AVPR1B, AVPR1A AVPR1B 2/4885HCRTR1 18/4885HCRTR2 14/4885
US-20140315914-A1 CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES AVPR2, AVPR1B, AVPR1A AVPR1B 2/4885HCRTR1 18/4885HCRTR2 14/4885
US-20110065720-A1 CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES AVPR2, AVPR1B, AVPR1A AVPR1B 2/4885HCRTR1 18/4885HCRTR2 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.